Literature DB >> 17968313

Downregulation of CCN3 expression as a potential mechanism for melanoma progression.

M Fukunaga-Kalabis1, G Martinez, S M Telson, Z-J Liu, K Balint, I Juhasz, D E Elder, B Perbal, M Herlyn.   

Abstract

Coculture of human melanocytes with keratinocytes upregulates CCN3, a matricellular protein critical to maintenance of normal homeostasis of melanocytes in the skin. CCN3 affects two fundamental features of melanocyte physiology: it inhibits melanocyte proliferation and stimulates their adhesion to the basement membrane. Here we report that expression of CCN3 is downregulated in advanced melanomas. Aggressive melanoma cell lines did not respond to treatment with CCN3 inducers, such as interleukin-1beta (IL-1beta), while less aggressive melanoma cell lines responded similarly to melanocytes. Immunostaining analyses revealed that CCN3 was present in melanoma cells close to the epidermal-dermal interface, but not in melanoma cells that had invaded deep into the dermis or had metastasized to lymph nodes. Contrary to our expectations, overexpression of CCN3 in 1205Lu metastatic melanoma cells did not affect their adhesion to collagen IV. However, CCN3 decreased the transcription and activation of matrix metalloproteinases and suppressed the invasion of 1205Lu melanoma cells. These results suggest that the lack of CCN3 in advanced melanoma cells contributes to their invasive phenotype. Whereas major matricellular proteins, such as osteopontin, tenascin or secreted protein acidic and rich in cysteine (SPARC), are strongly upregulated in melanoma cells; CCN3 is the first member of this family that is downregulated.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17968313      PMCID: PMC9048601          DOI: 10.1038/sj.onc.1210896

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  35 in total

1.  Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1.

Authors:  Ilunga Kalembeyi; Hiroyasu Inada; Rika Nishiura; Kyoko Imanaka-Yoshida; Teruyo Sakakura; Toshimichi Yoshida
Journal:  Int J Cancer       Date:  2003-05-20       Impact factor: 7.396

2.  Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.

Authors:  A Breslow
Journal:  Ann Surg       Date:  1970-11       Impact factor: 12.969

3.  SPARC represses E-cadherin and induces mesenchymal transition during melanoma development.

Authors:  Guillaume Robert; Cédric Gaggioli; Olivier Bailet; Carine Chavey; Patricia Abbe; Edith Aberdam; Emilie Sabatié; Amparo Cano; Antonio Garcia de Herreros; Robert Ballotti; Sophie Tartare-Deckert
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

4.  Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas.

Authors:  D Massi; A Franchi; L Borgognoni; U M Reali; M Santucci
Journal:  Hum Pathol       Date:  1999-03       Impact factor: 3.466

Review 5.  Adhesion, migration and communication in melanocytes and melanoma.

Authors:  Nikolas K Haass; Keiran S M Smalley; Ling Li; Meenhard Herlyn
Journal:  Pigment Cell Res       Date:  2005-06

6.  Osteopontin expression correlates with melanoma invasion.

Authors:  Youwen Zhou; Derek L Dai; Magdalena Martinka; Mingwan Su; Yi Zhang; Eric I Campos; Irene Dorocicz; Liren Tang; David Huntsman; Colleen Nelson; Vincent Ho; Gang Li
Journal:  J Invest Dermatol       Date:  2005-05       Impact factor: 8.551

7.  NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism.

Authors:  M Laurent; C Martinerie; H Thibout; M P Hoffman; F Verrecchia; Y Le Bouc; A Mauviel; H K Kleinman
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

8.  CCN5 is a growth arrest-specific gene that regulates smooth muscle cell proliferation and motility.

Authors:  Andrew C Lake; Ann Bialik; Kenneth Walsh; John J Castellot
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

9.  Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.

Authors:  U B Hofmann; J R Westphal; E T Waas; A J Zendman; I M Cornelissen; D J Ruiter; G N van Muijen
Journal:  Br J Cancer       Date:  1999-11       Impact factor: 7.640

Review 10.  Tumour progression and the nature of cancer.

Authors:  W H Clark
Journal:  Br J Cancer       Date:  1991-10       Impact factor: 7.640

View more
  37 in total

1.  CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.

Authors:  Véronique Ouellet; Kerstin Tiedemann; Anna Mourskaia; Jenna E Fong; Danh Tran-Thanh; Eitan Amir; Mark Clemons; Bernard Perbal; Svetlana V Komarova; Peter M Siegel
Journal:  Am J Pathol       Date:  2011-05       Impact factor: 4.307

2.  CCN3: the-pain-killer inside me.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2012-03-30       Impact factor: 5.782

3.  CCN3-mediated promotion of sulfated proteoglycan synthesis in rat chondrocytes from developing joint heads.

Authors:  Danilo Janune; Satoshi Kubota; Noureddine Lazar; Bernard Perbal; Seiji Iida; Masaharu Takigawa
Journal:  J Cell Commun Signal       Date:  2011-05-11       Impact factor: 5.782

4.  CCN proteins: A centralized communication network.

Authors:  Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2013-02-19       Impact factor: 5.782

5.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

6.  CCN3 suppresses TGF-β1-induced extracellular matrix accumulation in human mesangial cells in vitro.

Authors:  Hai-Fei Liu; Hong Liu; Lin-Li Lv; Kun-Ling Ma; Yi Wen; Long Chen; Bi-Cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

7.  CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.

Authors:  L Wu; C Runkle; H-J Jin; J Yu; J Li; X Yang; T Kuzel; C Lee; J Yu
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

8.  Matricellular protein CCN3 (NOV) regulates actin cytoskeleton reorganization.

Authors:  Wun-Chey Sin; Mimi Tse; Nathalie Planque; Bernard Perbal; Paul D Lampe; Christian C Naus
Journal:  J Biol Chem       Date:  2009-08-25       Impact factor: 5.157

9.  CCN3: a key growth regulator in Chronic Myeloid Leukaemia.

Authors:  Lynn McCallum; Wanhua Lu; Susan Price; Noureddine Lazar; Bernard Perbal; Alexandra E Irvine
Journal:  J Cell Commun Signal       Date:  2009-07-22       Impact factor: 5.782

10.  CCN3 and bone marrow cells.

Authors:  Ken-Ichi Katsube; Saki Ichikawa; Yuko Katsuki; Tasuku Kihara; Masanori Terai; Lester F Lau; Yoshihiro Tamamura; Shin'ichi Takeda; Akihiro Umezawa; Kei Sakamoto; Akira Yamaguchi
Journal:  J Cell Commun Signal       Date:  2009-07-23       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.